论文部分内容阅读
目的:观察灯盏花素针联合西医治疗急性脑梗死临床疗效。方法:将急性脑梗死患者70例随机分为2组各35例,对照组给予常规治疗,观察组在对照组基础上给予灯盏花素治疗,于治疗前、治疗后1天分别评价2组患者神经功能缺损(NIHSS)评分、生活自理能力及血浆半胱氨酸(Hcy)变化情况,2组临床疗效及不良反应情况。结果:2组治疗后NIHSS评分及日常生活能力评分、Hcy水平比较,差异无统计学意义(P>0.05);2组治疗后NIHSS评分、Brathel指数、Hcy水平均较治疗前改善(P<0.05),观察组改善程度较对照组显著(P<0.05)。总有效率观察组94.3%,对照组68.6%,2组比较,差异有统计学意义(P<0.05)。观察组:呕吐1例。对照组:呕吐4例,腹泻2例,皮疹3例。观察组不良反应率2.9%,低于对照组25.7%(χ2=14.53,P=0.00)。结论:灯盏花素针联合西医治疗急性脑梗死疗效显著且安全。
Objective: To observe the clinical efficacy of Breviscapine combined with western medicine in the treatment of acute cerebral infarction. Methods: Seventy patients with acute cerebral infarction were randomly divided into two groups of 35 cases. The control group was given routine treatment. The observation group was given breviscapine treatment on the basis of the control group. Before treatment and one day after treatment, two groups of patients Neurological deficit (NIHSS) score, self-care ability and plasma cysteine (Hcy) changes, two groups of clinical efficacy and adverse reactions. Results: There was no significant difference in NIHSS score, daily living ability score and Hcy level between the two groups after treatment (P> 0.05), NIHSS score, Brathel index and Hcy level after treatment ), The observation group improved more significantly than the control group (P <0.05). The total effective rate was 94.3% in the observation group and 68.6% in the control group. There was significant difference between the two groups (P <0.05). Observation group: vomiting in 1 case. Control group: vomiting in 4 cases, diarrhea in 2 cases, 3 cases of rash. Adverse reaction rate in observation group was 2.9%, which was lower than 25.7% in control group (χ2 = 14.53, P = 0.00). Conclusion: Breviscapine combined with western medicine has significant and safe therapeutic effect on acute cerebral infarction.